Urinary and Plasma Cell-Free DNA Comparison for Lung Cancer Patients Treated With Epidermal Growth Factor Receptor-Thyroxine Kinase Inhibitors.
Mutations in the EGFR gene are known to affect treatment efficacy. Comparison of urinary and plasma cell-free DNA allows possible noninvasive probing of disease mutations. A total of 130 patients with known epidermal growth factor receptor (EGFR) mutations derived from tissue biopsies were enrolled. Patients received thyroxine kinase inhibitor therapy. Peripheral blood and urine specimens were collected at different time intervals and processed using digital droplet polymerase chain reaction. Concordance between specimens and the prognostic utility were evaluated with an observational study. Prior to treatment, we observed an overall agreement of 86.2% between tumor tissue and cell-free DNA. Spearman rank correlation coefficient showed a strong correlation between plasma and urinary DNA results. In serial measurements following thyroxine kinase inhibitor therapy, secondary EGFR T790M mutation was observed. This occurred in 45% and 30% of non-small cell lung cancer patients with urine and plasma samples, respectively. Progression-free survival of patients with T790M mutation had a worse outcome and hazard ratios for the study cohort using urinary and plasma DNA were 5.3 and 3.5, respectively. Both urinary and plasma DNA presents new opportunities to detect mutations in non-small cell lung cancer patients and provide real-time updates to genetic profiles needed for treatment. In the current study, plasma DNA demonstrated better positive predictive value at baseline. For serial monitoring, we observed that changes in the T790M profiles were detected earlier in urine samples. The prognostic value of the assay can possibly aid in early clinical interventions.